Scilex Holding Co.

As of May 12, 2023, Scilex Holding Co. is considered risky and overvalued due to negative financial metrics, including a P/B ratio of -2.00 and an EV/EBITDA of -5.15, alongside a year-to-date stock performance of -66.63%, significantly underperforming the S&P 500's 2.44%.

As of June 20, 2025, the market trend is mildly bearish, influenced by daily moving averages and tempered by mixed signals from weekly indicators, despite some bullish momentum in the RSI.

Scilex Holding Co. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $5 million and a net loss of $26 million as of March 2025. It has a market cap of $310.97 million and key metrics indicating it is currently loss-making with no dividend yield.

As of Jun 18, Scilex Holding Co. has a market capitalization of 310.97 million and reported net sales of 50.71 million with a net profit of -74.51 million over the latest four quarters. The balance sheet shows shareholder's funds of -192.64 million and total assets of 92.95 million.